

TRAIL receptor 2 agonists - Pipeline Insight, 2022

<https://marketpublishers.com/r/TB3BB3E6D6FDEN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: TB3BB3E6D6FDEN

Abstracts

This report can be delivered to the clients within 2-3 Business Days

DelveInsight's, "TRAIL receptor 2 agonists - Pipeline Insight, 2022" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in TRAIL receptor 2 agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

TRAIL receptor 2 agonists Understanding

TRAIL receptor 2 agonists: Overview

TRAIL receptor 2 (TRAILR2), also known as Death receptor 5 (DR5), is a cell surface receptor of the TNF-receptor superfamily that binds TRAIL and mediates apoptosis. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) preferentially induces apoptosis in neoplastic cells upon binding to its receptors TRAIL-R1 and TRAIL-R2. This biological principle has been adopted for the development of cancer-selective therapies. However, many tumor cells are resistant to TRAIL and moreover TRAIL-R1/R2 can activate pro-inflammatory pathways thereby promoting invasion, migration, and metastasis

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence TRAIL receptor 2 agonists R&D. The therapies under development are focused on novel approaches for TRAIL receptor 2 agonists.

TRAIL receptor 2 agonists Emerging Drugs Chapters

This segment of the TRAIL receptor 2 agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

TRAIL receptor 2 agonists Emerging Drugs

INBRX-109: Inhibrx

INBRX-109 is a tetravalent DR5 agonistic antibody, is designed to exploit tumor-biased direct cell death induction by DR5 activation in numerous cancer types. With a valency of four, it has the ability to potently agonize DR5 through efficient receptor clustering, causing cell death, but by way of our sdAb platform, also eliminates recognition by pre-existing anti-drug antibodies (ADAs) to lessen the potential for hyper-clustering. In January 2021, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to INBRX-109 for the treatment of patients with unresectable or metastatic conventional chondrosarcoma.

BI 905711: Traverre Therapeutics

BI 905711 is a tetravalent bispecific antibody that cross-links the pro-apoptotic tumor necrosis factor (TNF)-related apoptosis-inducing ligand receptor 2 (TRAILR2) with the tumor cell anchor cadherin 17 (CDH17). CDH17-dependent clustering of TRAILR2 allows BI 905711 to induce selective apoptosis in CDH17-expressing tumor cells. BI 905711 is currently being investigated in patients with advanced gastrointestinal (GI) cancers.

Further product details are provided in the report.....

TRAIL receptor 2 agonists: Therapeutic Assessment

This segment of the report provides insights about the different TRAIL receptor 2 agonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on TRAIL receptor 2 agonists

There are approx. 5+ key companies which are developing the TRAIL receptor 2 agonists. The companies which have their TRAIL receptor 2 agonists drug candidates in the most advanced stage, i.e. Phase II include, Inhibrx.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

TRAIL receptor 2 agonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

TRAIL receptor 2 agonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TRAIL receptor 2 agonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TRAIL receptor 2 agonists drugs.

TRAIL receptor 2 agonists Report Insights

- TRAIL receptor 2 agonists Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

TRAIL receptor 2 agonists Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

- How many companies are developing TRAIL receptor 2 agonists drugs?

How many TRAIL receptor 2 agonists drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of TRAIL receptor 2 agonists?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the TRAIL receptor 2 agonists therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for TRAIL receptor 2 agonists and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Inhibrx

Boehringer Ingelheim

IGM Biosciences

Amgen

Genmab

Theraly Fibrosis

IGM Biosciences

Key Products

INBRX-109

BI 905711

IGM 8444

Conatumumab

Benufutamab

TLY 012

Anti-DR5 IgM antibody

Contents

Introduction

Executive Summary

TRAIL receptor 2 agonists: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

TRAIL receptor 2 agonists – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

INBRX-109: Inhibrx

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

BI 905711: Boehringer Ingelheim

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis
TLY 012: Theraly Fibrosis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
Comparative Analysis
TRAIL receptor 2 agonists Key Companies
TRAIL receptor 2 agonists Key Products
TRAIL receptor 2 agonists- Unmet Needs
TRAIL receptor 2 agonists- Market Drivers and Barriers
TRAIL receptor 2 agonists- Future Perspectives and Conclusion
TRAIL receptor 2 agonists Analyst Views
TRAIL receptor 2 agonists Key Companies
Appendix

I would like to order

Product name: TRAIL receptor 2 agonists - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/TB3BB3E6D6FDEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TB3BB3E6D6FDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970